BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 3,857 Shares of Illumina, Inc. (NASDAQ:ILMN)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,575 shares of the life sciences company's stock after selling 3,857 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in Illumina were worth $3,466,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Edgestream Partners L.P. raised its stake in Illumina by 27.9% during the third quarter. Edgestream Partners L.P. now owns 12,212 shares of the life sciences company's stock worth $1,593,000 after acquiring an additional 2,661 shares during the period. Fred Alger Management LLC acquired a new position in shares of Illumina during the third quarter valued at approximately $1,121,000. Captrust Financial Advisors increased its stake in shares of Illumina by 6.5% during the third quarter. Captrust Financial Advisors now owns 8,576 shares of the life sciences company's stock valued at $1,118,000 after acquiring an additional 524 shares during the period. Vinva Investment Management Ltd bought a new stake in Illumina during the third quarter worth approximately $859,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company's stock worth $164,334,000 after buying an additional 54,319 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. UBS Group raised their price target on shares of Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Robert W. Baird lifted their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. Hsbc Global Res upgraded shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price target on the stock in a research report on Thursday, October 17th. Finally, Scotiabank decreased their target price on shares of Illumina from $176.00 to $164.00 and set a "sector outperform" rating on the stock in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $164.00.

Illumina Trading Up 1.4 %

Shares of Illumina stock traded up $1.90 on Wednesday, hitting $142.50. The stock had a trading volume of 1,410,359 shares, compared to its average volume of 2,021,730. The stock's 50-day simple moving average is $142.74 and its two-hundred day simple moving average is $126.57. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The stock has a market cap of $22.60 billion, a price-to-earnings ratio of -14.31 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter last year, the firm posted $0.33 earnings per share. The company's revenue for the quarter was down 3.5% on a year-over-year basis. As a group, sell-side analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.